BD is pairing up with Labcorp to develop a new line of companion diagnostics for cancer treatments and therapies for other diseases, analyzing patients’ cells using flow cytometry technology to match ...

Medical technology company Becton, Dickinson and Co. is partnering with life sciences company Labcorp to develop cytometry-based companion diagnostics that can be used to match patients with ...

FRANKLIN LAKES, N.J., Aug. 9, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp ...

Flow cytometry is a powerful, emerging technology that can help medical professionals better understand disease, according to Dr. Bill Hanlon, chief scientific officer of Labcorp Drug Development.

Labcorp is partnering with BD to develop flow cytometry-based companion diagnostics for diseases including cancer. The companies will collaborate with biopharmaceutical partners for exploratory panel ...

Becton, Dickinson and Company BDX, popularly known as BD, recently entered into a collaboration with Laboratory Corporation of America Holdings LH or LabCorp. The tie-up is aimed at creating a ...

Becton Dickinson & Co. and Laboratory Corp. of America Holdings (Labcorp)are teaming up to develop, market and commercialize flow cytometry-based companion diagnostics (CDx) for cancer and other ...